freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-11. Anything still debated is marked as such rather than presented as settled.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
=== February === 1 February Mike Behrens, lawyer and judge, King's Counsel (since 1999), District Court judge (2004–2011) (born 1941). Dame Iritana Tāwhiwhirangi, Māori language advocate (born 1929). 2 February – Peter Babich, Hall of Fame viticulturist and businessman (born 1932). 5 February – Brian Turner, field hockey player (national team), poet and environmental campaigner, Commonwealth Poetry Prize (1999), Poet Laureate (2003–2005) (born 1944). 6 February – Jim Cole, volcanologist (University of Canterbury), Fellow of the Royal Society of New Zealand (since 2004) (born 1941). 7 February – Ian Barton, forester, heritage advocate (Queen's Redoubt Trust), and local-body politician, Franklin District Councillor (1998–2004) (born 1937). 10 February Lynne Giddings, nursing and women's studies academic (Auckland University of Technology, University of Auckland) (born 1945). Toni Huata, Māori musician (born 1969). Rod McElrea, racing driver, national beach racing champion (1971), OSCA champion (1983) (born 1941). 12 February – Theo Janssen, sculptor, stained-glass artist and painter (born 1934). 13 February – Joe Pope, business executive (Petrocorp, ENZA) and rugby administrator, chair of Hurricanes franchise (1999–2003) and Wellington Rugby Football Union (2003–2009) (born 1941). 15 February David Ellison, Māori leader (Kāti Huirapa), veterans' welfare and children's health advocate (born 1936). David Parsons, musician, composer and ethnomusicologist (born 1944). 17 February – David Saunders, lawyer and judge, District Court judge (1993–2020) (born c. 1951).
=== Chiral crown ether === Chiral crown stationary phases consist Crown ethers, immobilized or bonded to the support particles, are polyethers with a macrocyclic structure that can create host-guest complexes with alkali, earth-alkali metal ions, and ammonium cations. The skeleton of the cyclic structure is composed of oxygen and methylene groups arranged alternately. The electron-donating ether oxygens are positioned within the inner wall of the crown cavity, and are encircled by methylene groups in a collar-like arrangement. The chiral recognition is based on two distinct diastereomeric inclusion complexes that can be generated. The primary interactions facilitating complexation involve hydrogen bonds, formed between the three amine hydrogens and the oxygens of the macrocyclic ether, arranged in a tripod configuration. Additionally, ionic interactions, dipole-dipole interactions, or hydrogen bonds can occur between the carbocyclic groups and polar groups of the analytes, providing further support for the complexes.
The Japanese Hisatugu Numata developed the first panoramic radiograph in 1933/34. This was followed by the development of intraoral panoramic X-ray units, in which the X-ray tube is placed intraorally (inside the mouth) and the X-ray film extraorally (outside the mouth). At the same time, Horst Beger from Dresden in 1943 and the Swiss dentist Walter Ott in 1946 worked on the Panoramix (Koch & Sterzel), Status X (Siemens) and Oralix (Philips). Intraoral panoramic devices were discontinued at the end of the 1980s because the radiation exposure was too high in direct contact with the tongue and oral mucosa due to the intraoral tube.
Sources: en.wikipedia.org
When winemakers select a cultured yeast strain, it is largely done because the winemaker wants a predictable fermentation taken to completion by a strain that has a track record of dependability. Among the particular considerations that are often important to winemakers is a yeast's tendency to:
{\displaystyle {\frac {\left({\sqrt {a}}-{\sqrt {b}}\right)^{2}+\left({\sqrt {b}}-{\sqrt {c}}\right)^{2}+\left({\sqrt {c}}-{\sqrt {a}}\right)^{2}}{\left({\sqrt {a}}+{\sqrt {b}}+{\sqrt {c}}\right)^{2}}}\leq {\frac {4}{9}}\left({\frac {R}{r}}-2\right).}
Whether or not a person manages to elevate their baseline to the heights of their genetic possibilities depends partly on several factors, including actions and habits. Some happiness-boosting habits seem to include gratitude, appreciation, and even altruistic behavior. Other research-based habits and techniques for increasing happiness are discussed on this page. Besides the development of new habits, the use of antidepressants, effective exercise, and a healthier diet have proven to affect mood significantly. There is evidence that a vegan diet reduces stress and anxiety. Exercise is sometimes called the "miracle" or "wonder" drug – alluding to the wide variety of proven benefits it provides. A 2010 book, Anatomy of an Epidemic, challenges the use of non-conservative usage of medications for mental patients, specially with respect to their long-term positive feedback effects. Yongey Mingyur Rinpoche has said that neuro scientists have found that with meditation, an individual's happiness baseline can change. and meditation has been found to increase happiness in several studies. A study on Brahma Kumaris Raja yoga meditators showed them having higher happiness (Oxford happiness questionnaire) than the control group.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。